Enanta Pharma (ENTA) Adds Innocoll Holdings' Russell as Director
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St loses over 1% amid fading rate-cut hopes
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steadies as US fuel demand concerns face Middle East supply risks
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Enanta Pharmaceuticals Announces the Appointment of Dr. Lesley Russell to Its Board of Directors
November 22, 2016 7:30 AM ESTWATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Lesley Russell, MBChB, MRCPb, to its Board of Directors. Dr. Russell will also serve as a member of Enantas audit committee and its nominating and corporate governance committee, effective as of January 1, 2017.
Dr. Russell has over two decades of clinical, regulatory and drug development expertise in the therapeutic areas of hematology/oncology, neurology, psychiatry, pain and inflammation, respiratory medicine,... More
